ChiCTR2000039506 版本V1.0 版本创建时间2020/10/30 17:34:32 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2000039506 

最近更新日期:

Date of Last Refreshed on:

2020-10-30 17:34:25 

注册时间:

Date of Registration:

2020-10-30 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

李彩霞医师:该研究尚未获得伦理委员会批准,请于批准后再开始纳入参试者,并与我们联系上传批件。 辅助咨询在提高乙肝患者肝癌筛查依从的效果评价:一项随机对照研究

Public title:

The effects of counseling on improving hepatocellular carcinoma screening among patients with hepatitis B infection: A Randomized Controlled Trial

注册题目简写:

English Acronym:

研究课题的正式科学名称:

Pilot Testing, and Evaluation of a Nurse-led Decision Counseling Program to Improve Decision-making and Uptake of Hepatocellular Carcinoma Screening Among Patients with Hepatitis B Virus Infection: A Randomized Controlled Trial

Scientific title:

护士主导的决策咨询在提高乙肝患者肝癌筛查决策和使用的效果评价:一项随机对照研究

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

李彩霞 

研究负责人:

李彩霞 

Applicant:

LI Caixia 

Study leader:

LI Caixia 

申请注册联系人电话:

Applicant telephone:

85252610019

研究负责人电话:

Study leader's
telephone:

85252610019

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

caixiali@link.cuhk.edu.hk

研究负责人电子邮件:

Study leader's E-mail:

caixiali@link.cuhk.edu.hk

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

香港中文大学那打素护理学院利黄瑶璧楼604

研究负责人通讯地址:

香港中文大学那打素护理学院利黄瑶璧楼604

Applicant address:

Room 604, 6/F, Esther Lee Building, the Chinese University of Hong Kong, Shatin, NT, Hong Kong

Study leader's address:

Room 604, 6/F, Esther Lee Building, the Chinese University of Hong Kong, Shatin, NT, Hong Kong

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

香港中文大学,那打素护理学院

Applicant's institution:

The Nethersole School of Nursing, the Chinese University of Hong Kong

研究负责人所在单位:

香港中文大学,那打素护理学院

Affiliation of the Leader:

The Nethersole School of Nursing, the Chinese University of Hong Kong

是否获伦理委员会批准:

Approved by ethic committee:

No

伦理委员会批件文号:

Approved No. of ethic committee:

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

Name of the ethic committee:

伦理委员会批准日期:

Date of approved by ethic committee:

2013-08-26 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

香港中文大学那打素护理学院

Primary sponsor:

The Nethersole School of Nursing, the Chinese University of Hong Kong

研究实施负责(组长)单位地址:

香港中文大学,那打素护理学院,利黄瑶璧楼,沙田,香港,中国

Primary sponsor's address:

Esther Lee Building, the Nethersole School of Nursing, the Chinese University of Hong Kong, Shatin, NT, Hong Kong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

香港

市(区县):

Country:

China

Province:

Hong Kong

City:

单位(医院):

香港中文大学那打素护理学院

具体地址:

沙田区沙田大学道

Institution
hospital:

The Nethersole School of Nursing, the Chinese University of Hong Kong

Address:

Shatian University Avenue, Shatin District

经费或物资来源:

自筹

Source(s) of funding:

No funding

研究疾病:

乙肝  

Target disease:

Hepatitis B

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

探讨咨询在提高乙肝患者进行肝癌筛查决策和依从的干预效果  

Objectives of Study:

To evaluate the effects of counseling on improving decision-making and uptake of hepatocellular carcinoma screening among patients with hepatitis B infection.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

本研究将纳入乙肝患者,年龄为18-65岁。根据指南推荐适合进行肝癌筛查,包括:合并肝硬化、男性年龄 > 40岁、女性年龄 > 50岁或有肝癌家族史。根据中华人民共和国国家卫生健康委员会医政医管局推荐:高危人群应至少每6个月进行一次肝脏超声联合血清甲胎蛋白筛查。因此,在过去6个月内未进行以上检查的患者将纳入本研究。

Inclusion criteria

The target population is the patients with HBV infection. Inclusion criteria are as follows: (1) patients with HBV infection (HBsAg positive), aged 18-65 years old; (2) have been recommended to have HCC screening, including liver cirrhosis, males over age 40, women over age 50, and family history of HCC; (3) can understand Chinese; and (4) without an liver ultrasound or serum alpha-fetoprotein test in the previous six months at the time of inclusion. The screening tests and interval are chose based on hepatocellular carcinoma surveillance guideline in mainland China.

排除标准:

研究将排除合并其他疾病的患者,包括联合丙肝感染等其他慢性肝脏疾病;有肝癌诊断史或肝移植史;有肝性脑病、精神病史、消化道出血等影响患者参与研究的疾病;或不愿意参与本研究。

Exclusion criteria:

The exclusion criteria includes: (1) have comorbid condition, including co-infection with hepatitis C, human immunodeficiency virus, and alcoholic liver disease, (2) have HCC diagnosis; (3) have undergone liver transplantation; (4) have encephalopathy; or (5) not willing to participate.

研究实施时间:

Study execute time:

From 2021-01-01 00:00:00 To 2021-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2021-09-30 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

96

Group:

Intervention group

Sample size:

干预措施:

咨询

干预措施代码:

Intervention:

Counseling

Intervention code:

组别:

对照组

样本量:

96

Group:

Control group

Sample size:

干预措施:

常规护理

干预措施代码:

Intervention:

Usual care

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

河南 

市(区县):

郑州 

Country:

China

Province:

He'nan

City:

Zhengzhou

单位(医院):

河南省人民医院 

单位级别:

三级甲等 

Institution
hospital:

He'nan Provincial People's Hospital

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

肝癌筛查率

指标类型:

主要指标

Outcome:

Hepatocellular carcinoma screening uptake rates

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

肝癌筛查知识

指标类型:

次要指标

Outcome:

Hepatocellular carcinoma screening knowledge

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

预防性健康理论模型构念

指标类型:

次要指标

Outcome:

Preventive health model constructs

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

决策冲突

指标类型:

次要指标

Outcome:

Decision conflict

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

Not applicable

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

研究不涉及人体标本

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

有独立的统计师根据电脑产生的随机数字

Randomization Procedure (please state who generates the random number sequence and by what method):

An independent statistician will generate random sequences using a computerized random number generation.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

通过联系研究者获取原始数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

By asking the researcher

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集根据电子医疗系统以及患者填写的调查问卷。数据的保存将由研究者进行,并遵循匿名和保密原则。电子数据将用密码保护,纸质版数据将封锁在柜子中。所有的数据在研究结束后5年内销毁。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection will be based on medical electronic system and participants' self-reported data on questionnaires. Anonymity and confidentiality will be adhered when managing and storing data.A password will be required to access data each time. A back of data will be stored on an external jump possessing the same security measures. The physical data will be locked in a cabinet, only accessible by the researcher. All the documents would be completely destroyed five years after completion of the research project.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-10-30 17:34:25